RIGEL PHARMACEUTICALS, INC. Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss
RIGEL PHARMACEUTICALS, INC. (RIGL) had Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss of $27.00 thousand as of 2018-12-31, per its 10-K filed 2019-02-28.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss · last filed 2019-02-28
- 2018-12-31: Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss $27.00K.
- 2017-12-31: Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss $83.00K.
- 2016-12-31: Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss $23.00K.
- 2015-12-31: Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss $56.00K.
| Period end | Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss |
|---|---|
| 2018-12-31 | $27.00K 10-K · filed 2019-02-28 |
| 2017-12-31 | $83.00K 10-K · filed 2018-03-06 |
| 2016-12-31 | $23.00K 10-K · filed 2017-03-07 |
| 2015-12-31 | $56.00K 10-K · filed 2016-03-08 |
| 2014-12-31 | $32.00K 10-K · filed 2015-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |